Danaher Completes Acquisition of Patient Monitoring Technology Firm Masimo
Advertisement
The latest development follows an earlier announced agreement between Danaher to acquire California-based health monitoring technology company for $180 per share, amounting to approximately $9.9 billion.
Danaher, a global science and technology innovator, has announced the completion of the acquisition of Masimo, a leading speciality diagnostics provider and patient monitoring solutions, primarily in acute care treatment settings.
The latest development follows an earlier announced agreement between Danaher to acquire California-based health monitoring technology company for $180 per share, amounting to approximately $9.9 billion.
The acquisition brings Masimo’s portfolio of digital health and patient monitoring solutions to Danaher's diagnostic business.
The solutions include its pulse oximetry technologies, advanced sensor platforms, and AI-enabled monitoring systems. In addition, Masimo’s portfolio also includes the W1 wearable health monitoring smartwatch.
Following the completion of the deal, Masimo will operate a wholly-owned subsidiary, maintaining its existing brand and operating as a standalone company within the Danaher Diagnostics segment.
Commenting on the new development, Julie Sawyer Montgomery, Executive Vice President of Diagnostics at Danaher, said, “Masimo is a strong strategic fit for Danaher. Together, we expect to strengthen our ability to deliver differentiated products in acute care settings and accelerate Masimo's growth and global reach.”
Last year, the subsidiary arm of the Washington-based global science and technology company in India, Danaher, partnered with the Translational Health Science and Technology Institute (THSTI).
The partnership seeks to strengthen India’s biomanufacturing ecosystem by focusing on capability building and infrastructure development in life sciences, biotechnology, and healthcare solutions.
The latest acquisition is expected to strengthen Danaher’s footprint in the healthcare technology and diagnostics market, adding a leading patient monitoring business to its portfolio of life sciences, biotechnology, and diagnostic companies.
Stay tuned for more such updates on Digital Health News
